Elicio Therapeutics (ELTX)
NASDAQ:ELTX
Want to see ELTX full AI Analyst Report?
Top Page
Elicio Therapeutics
(NASDAQ:ELTX)
Select Model
Select Model
Rating:51Neutral
Price Target:
$14.00
▲(3.32% Upside)
Action:Reiterated
Date:06/05/26
Overall score reflects a sharp mismatch between strong recent price momentum (above major moving averages with positive MACD) and weak fundamentals (no revenue, large losses, significant cash burn, and negative equity). Valuation metrics provide limited support given negative earnings and no dividend yield data.
Positive Factors
Peer-reviewed validation of AMP platform
A peer-reviewed Science Advances publication materially strengthens scientific validation of Elicio's AMP platform, increasing credibility with investigators, partners and regulators. This durable endorsement can support longer-term collaborations, licensing and broader application across oncology and infectious disease.
Negative Factors
No revenue; clinical-stage commercialization risk
As a clinical-stage biotech with no product revenue, Elicio depends on successful clinical outcomes and external financing to reach commercialization. This structural lack of revenue means long development timelines, binary clinical risks and ongoing funding needs until product approvals or partnerships deliver durable income.
Read all positive and negative factors
Positive Factors
Negative Factors
Peer-reviewed validation of AMP platform
A peer-reviewed Science Advances publication materially strengthens scientific validation of Elicio's AMP platform, increasing credibility with investigators, partners and regulators. This durable endorsement can support longer-term collaborations, licensing and broader application across oncology and infectious disease.
Read all positive factors
Elicio Therapeutics (ELTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$265.87M
Dividend YieldN/A
Average Volume (3M)77.23K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue GrowthN/A
EPS Growth43.68%
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.36
Shares Outstanding19,086,080
10 Day Avg. Volume85,490
30 Day Avg. Volume77,231
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-720.63
Enterprise Value/Ebitda-5.65
Forecast
1Y Price Target
$18.00Price Target Upside32.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.86
Revenue Forecast (FY)N/A
Elicio Therapeutics Business Overview & Revenue Model
Company Description
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccin...
How the Company Makes Money
null...
Elicio Therapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.31M |
| Gross Profit | -289.00K | -1.13M | -1.18M | -1.17M | -1.06M | 27.08M |
| EBITDA | -36.87M | -36.59M | -50.27M | -32.97M | -23.55M | -51.92M |
| Net Income | -40.19M | -39.57M | -51.90M | -35.20M | -28.21M | -26.40M |
Balance Sheet | ||||||
| Total Assets | 22.69M | 25.86M | 28.18M | 27.15M | 22.66M | 96.51M |
| Cash, Cash Equivalents and Short-Term Investments | 14.95M | 18.56M | 17.62M | 12.89M | 7.80M | 88.76M |
| Total Debt | 4.87M | 14.51M | 26.04M | 6.92M | 7.48M | 4.66M |
| Total Liabilities | 24.13M | 24.23M | 39.49M | 15.77M | 13.75M | 15.01M |
| Stockholders Equity | -1.44M | 1.64M | -11.31M | 11.37M | 8.91M | 81.51M |
Cash Flow | ||||||
| Free Cash Flow | -38.49M | -36.97M | -37.16M | -32.76M | -22.83M | -24.46M |
| Operating Cash Flow | -38.48M | -36.95M | -37.07M | -32.69M | -22.18M | -23.94M |
| Investing Cash Flow | -16.00K | -16.00K | -84.00K | -32.00K | -654.00K | -525.36K |
| Financing Cash Flow | 34.39M | 36.70M | 42.32M | 38.61M | 21.20M | 19.39M |
Elicio Therapeutics Technical Analysis
Positive
13.55
Price Trends
11.01
Positive
10.41
Positive
10.00
Positive
Market Momentum
0.53
Negative
62.83
Neutral
80.18
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTX, the sentiment is Positive. The current price of 13.55 is above the 20-day moving average (MA) of 10.98, above the 50-day MA of 11.01, and above the 200-day MA of 10.00, indicating a bullish trend. The MACD of 0.53 indicates Negative momentum. The RSI at 62.83 is Neutral, neither overbought nor oversold. The STOCH value of 80.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELTX.
Elicio Therapeutics Risk Analysis
Elicio Therapeutics disclosed 91 risk factors in its most recent earnings report. Elicio Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Elicio Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $209.91M | 5.70 | 47.72% | ― | 163.35% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $265.87M | -6.01 | -2748.16% | ― | ― | 43.68% | |
49 Neutral | $159.36M | ― | -339.38% | ― | ― | 17.64% | |
46 Neutral | $66.33M | -1.35 | -127.30% | ― | ― | 49.74% |
* Healthcare Sector Average
ELTX
Elicio Therapeutics
13.26
5.43
69.35%
CGEN
Compugen
2.10
0.36
20.69%
MCRB
Seres Therapeutics
6.63
-1.60
-19.44%
MIST
Milestone Pharmaceuticals
1.23
-0.50
-28.90%
ACTU
Actuate Therapeutics, Inc.
1.88
-7.08
-79.02%
Elicio Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Elicio Therapeutics Launches New $100 Million ATM Program
Neutral
Mar 16, 2026
On March 16, 2026, Elicio Therapeutics entered into a new at-the-market equity offering program of up to $100 million in common stock through B. Riley Securities, JonesTrading Institutional Services and Ladenburg Thalmann, giving the biotech flexi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.